Use of a false recognition paradigm in an Alzheimer's disease clinical trial: a pilot study.
We report the first use of a false recognition memory test in a clinical trial of patients with Alzheimer's disease (AD). Tests of false recognition allow measurement of two components of memory: the specific details of a prior encounter with a particular item (item-specific recollection) and the general meaning, idea, or gist conveyed by a collection of items (gist memory). We used a false recognition paradigm with categorized pictures to study the effects of an experimental medication in patients with AD. Because medications to treat AD may preferentially improve gist memory or item-specific recollection, use of this type of paradigm may improve sensitivity for detection of drug effects more than standard memory tests.
Budson
Andrew E
AE
Harvard Medical School, Boston, Massachusetts, USA. abudson@partners.org
Michalska
Kalina J
KJ
Rentz
Dorene M
DM
Joubert
Claire C
CC
Daffner
Kirk R
KR
Schacter
Daniel L
DL
Sperling
Reisa A
RA
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D062365:Aminobenzoates; D001288:Attention / Q000187:drug effects*; D003210:Concept Formation / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007042:Hypoxanthines; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010364:Pattern Recognition, Visual / Q000187:drug effects*; D010865:Pilot Projects; D011687:Purines
D062365:Aminobenzoates; D007042:Hypoxanthines; D018697:Nootropic Agents; D011687:Purines; C086241:4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid